News

The approved therapy Attruby (acoramidis) may not only slow the progression of transthyretin amyloid cardiomyopathy (ATTR-CM), but it may also help reverse heart…

In people with transthyretin amyloid cardiomyopathy (ATTR-CM), treatment with the approved therapy Amvuttra (vutrisiran) may help reduce the risk of death and serious heart…

A family history of nerve disease, carpal tunnel syndrome in both hands, and balance problems are the “clinical ‘red flags'” most strongly linked to a…

The first participant has been dosed in a clinical trial evaluating the long-term effects of Attruby (acoramidis), an approved treatment for transthyretin amyloid…

Hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN) should be treated as early as possible once a patient has symptoms and a confirmed disease-causing genetic mutation,…

Biopsies taken during surgery for carpal tunnel syndrome, a condition that affects a wrist nerve, may help with early detection of transthyretin cardiac…

Although mutations that cause hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN) most frequently lead to nerve damage, they can also cause heart damage and other…

Enrollment is open in a post-marketing clinical trial designed to investigate whether long-term treatment with Attruby (acoramidis) can reverse heart disease-related changes in people…

A specific genetic variant may have contributed to signs of severe liver problems observed in a few patients given nexiguran ziclumeran (nex-z), an investigational gene-editing…

Regulatory authorities in the European Union (EU) have recommended approval of Tafamidis Accord, a generic version of Vyndaqel (tafamidis), an approved treatment for adults with hereditary…